Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine. - Folschweiller N; Behre U; Dionne M; Durando P; Esposito S; Ferguson L; Ferguson M; Hillemanns P; McNeil SA; Peters K; Ramjattan B; Schwarz TF; et al. (The Journal of infectious diseases, 2019)